Evidence map›Paper›PMID 34339027›Full record

ArticleAdvances in experimental medicine and biology2021

Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Orlandric Miree, Sanjeev Kumar Srivastava, Santanu Dasgupta, Seema Singh, Rodney Rocconi, Ajay Pratap Singh

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Orlandric MireeDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL, USA.
Sanjeev Kumar SrivastavaDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL, USA.
Santanu DasguptaDepartment of Medicine, The University of Texas Health Science Center at Tyler, Tyler, TX, USA.
Seema SinghDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL, USA.
Rodney RocconiDivision of Gynecologic Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Ajay Pratap SinghDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL, USA. asingh@health.southalabama.edu.

Funding

Molecular determinant of racial disparity in prostate cancerU01CA185490 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2014 to 2018
$1.7M
NCI NIH HHS U01 CA185490
6 · The paper itself

Abstract

Ovarian cancer (OC) is the most lethal gynecological malignancy among women worldwide. In most cases, it is diagnosed late at an advanced stage and does not respond well to existing therapies leading to its poor prognosis. In addition, other factors including epidemiological, complex histological diversity, multiple molecular alterations, and overlapping signaling pathways are also important contributors to poor disease outcome. Efforts have continued to develop a deeper understanding of the molecular pathogenesis and altered signaling nodes that provide hope for better clinical management through the development of novel approaches for early diagnosis, disease subtyping, prognosis, and therapy. In this chapter, we provide a detailed overview of OC and its histological subtypes and discuss prevalent molecular aberrations and active signaling pathways that drive OC progression. We also summarize various diagnostic and prognostic markers and therapeutic approaches currently being employed and discuss emerging findings that hold the potential to change the future course of OC management.

Indexed as

Ovarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleHumansLymphatic MetastasisSignal TransductionMolecular alterationsOncogenic signalingOvarian cancerPrognosisTherapy

Identifiers

PMID34339027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.